For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ GHRP-6
Illustration for GHRP-6

THE PEPSRADAR ENCYCLOPEDIA

GHRP-6

Growth-hormone release

Research topics · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

GHRP-6 · KEY FACTS

Content updated · how dates work

Saved peptides

What is GHRP-6?

GHRP-6 is a growth-hormone secretagogue with effects extending beyond a single hormone. Human physiology studies help explain that distinction.

Biological role or research focus

Growth-hormone release.

A response in growth hormone is not itself a demonstrated recovery or performance outcome.

Role reference: Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. ↗

Names you may encounter

GHRP 6 · GHRP6

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Synthetic growth-hormone-releasing peptide
Main research area
Endocrine and sleep physiology
Evidence featured
Human physiology experiment
Source check
October 4, 2026

Source: Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. ↗

Quick answers

Is GHRP-6 FDA approved?
No. No FDA-approved drug contains GHRP-6. FDA lists it in 503A category 3: nominated for compounding without enough supporting information. Source ↗
Is GHRP-6 safe?
GHRP-6 is an unapproved growth-hormone secretagogue. Short human studies show it also raises cortisol and ACTH, and FDA cites possible blood-sugar effects and immune-reaction risk. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
Is GHRP-6 banned in sport?
Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.4 Growth hormone releasing factors). Source ↗
Has the FDA taken action over GHRP-6?
Yes. Our records list 1 FDA action naming it, most recently on April 1, 2020: FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing GHRP-6 among bulk substances that are not eligible for 503A compounding exemptions. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

2 Human research
StudyTypePopulation / model
Sleep and hormone experiment (1995)Human physiology experimentHealthy male volunteers.
GHRP-6 · diagnostic GH responses (1996)Human diagnostic studyShort-statured children and adults assessed for growth-hormone deficiency; participant counts are not supplied in the abstract.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human physiology experiment · 1995

Sleep and hormone experiment

Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man.

Population / model
Healthy male volunteers.
Study design
Repeated GHRP-6 or placebo administration with overnight hormone sampling and sleep EEG.
Main finding
Growth hormone, ACTH, and cortisol increased. Stage-2 sleep increased; slow-wave sleep did not.
Limits & context
The response was not restricted to growth hormone. An overnight physiology study does not establish treatment for chronic insomnia, injury recovery, or long-term athletic performance.

Source: Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. ↗

Human diagnostic study · 1996

GHRP-6 · diagnostic GH responses

Can a hormone response distinguish growth-hormone deficiency?

Population / model
Short-statured children and adults assessed for growth-hormone deficiency; participant counts are not supplied in the abstract.
Study design
Hormone-response comparisons after GHRP-6, including combined GHRH testing in selected groups.
Main finding
Average responses were lower in deficient patients, but individual results overlapped substantially with controls. Markedly reduced responses were reported with pituitary stalk transection.
How to read it
Different group averages do not automatically make a reliable individual diagnostic test.
Limits & context
Incomplete diagnostic-performance reporting prevents assessing sensitivity or specificity. A transient hormone response is not evidence of muscle gain, injury recovery, or a safe self-treatment regimen.

Source: Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency. ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

No study naming GHRP-6 as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.

Further reading · 3 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway. ↗
International heart journal · 2017 Apr 6 · Journal Article

N-aminoimidazolidin-2-one peptidomimetics. ↗
Organic letters · 2014 Apr 18 · Journal Article, Research Support, Non-U.S. Gov't

Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation. ↗
Journal of nanobiotechnology · 2025 Dec 1 · Journal Article
Read available full text ↗

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

GHRP-6 is an unapproved growth-hormone secretagogue. Short human studies show it also raises cortisol and ACTH, and FDA cites possible blood-sugar effects and immune-reaction risk.

Human safety data: Very limited

Human data come from small, short physiology and diagnostic studies. Long-term safety, including effects on blood sugar and stress hormones with repeated use, has not been studied.

Unassessed: little human safety data

Take extra care with: Diabetes or blood-sugar medicines

It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Interactions

  • Diabetes: may raise blood glucose by reducing insulin sensitivity (FDA)

Serious risks

  • FDA: possible rise in blood glucose from reduced insulin sensitivity
  • Raises the stress hormones cortisol and ACTH, not only growth hormone (human study)
  • FDA: possible immune reactions (immunogenicity) and peptide-impurity problems with compounded products

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Bulk drug substances that may present significant safety risks (category 2) ↗ · GHRP-6 stimulates sleep, GH, ACTH and cortisol in men (1995) ↗ · GHRP-6 test in the diagnosis of GH deficiency (1996) ↗ · Safety and efficacy of growth hormone secretagogues (review, 2018) ↗

Safety evidence & remaining uncertainty

The experiment’s broader endocrine response is relevant to safety interpretation. Its short duration cannot resolve effects of prolonged exposure or use with other hormone-active substances.

Source: Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Category 3 (nominated without enough support)
Listed in 503A category 3 ("GHRP-6", nominated without adequate support). Separately, FDA placed GHRP-6 in 503B category 2 (significant safety risks) on September 29, 2023. source
World Anti-Doping Agency (2026)
Prohibited, named on the list · S2.2.4 Growth hormone releasing factors
Named explicitly ("GHRP-6"). source

FDA actions

  • FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing GHRP-6 among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source

Other notes

  • FDA lists GHRP-6 in 503B category 2 for outsourcing facilities, citing immunogenicity risk and effects on cortisol and blood glucose. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & status

Research into overnight hormone patterns and sleep stages does not establish a treatment for insomnia, muscle loss, or injury recovery.

Source: Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Seller lab-report checks and prices are available to members. Sign up free

Mechanism & research rationale

The cited experiment found growth-hormone release alongside activation of ACTH and cortisol secretion. It therefore should not be described as an exclusively growth-hormone-specific signal.

Source: Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. ↗

Molecular structure

GHRP-6: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 4345065 ↗

Questions worth asking

  • What specific product, route, and research population does the claim refer to?
  • Does the source measure an outcome in people, or only a laboratory marker?
  • A response in growth hormone is not itself a demonstrated recovery or performance outcome.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Did it increase deep slow-wave sleep in this study?

No. Stage-2 sleep increased while slow-wave sleep did not.

Source: Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. ↗

Are GHRP-6 and GHRH the same substance?

No. They can both stimulate growth-hormone release, but their endocrine responses differed in this comparison.

Source: Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

GHRP-6

Download illustration ↓Source record ↗
GHRP-6 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.